Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
ImmunityBio (DE:26CA)
FRANKFURT:26CA
ImmunityBio (26CA) Stock Price & Analysis
0 Followers
26CA Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€1.17 - €6.60
Previous Close€5.06
Volume500.00
Average Volume (3M)1.15K
Market Cap
€3.45B
Enterprise Value€4.03B
Total Cash (Recent Filing)$266.46M
Total Debt (Recent Filing)$882.14M
Price to Earnings (P/E)N/A
Beta1.26
Next Earnings
Aug 09, 2023EPS Estimate
-€0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding673,952,278
10 Day Avg. Volume45
30 Day Avg. Volume1,152
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)-5.51
Price to Sales (P/S)22191.94
Price to Cash Flow (P/CF)-7.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue6.48K
Enterprise Value/Gross Profit6.48K
Enterprise Value/Ebitda-13.42
Forecast
1Y Price Target
€4.67Price Target Upside4.21% Upside
Rating ConsensusHold
Number of Analyst Covering1
ImmunityBio News
PremiumCompany Announcements
ImmunityBio’s FDA Approval and Planned Equity Expansion
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
0.04% Other Institutional Investors
99.96% Public Companies and
Individual Investors
26CA FAQ
What was ImmunityBio’s price range in the past 12 months?
ImmunityBio lowest stock price was €1.17 and its highest was €6.60 in the past 12 months.
What is ImmunityBio’s market cap?
Currently, no data Available
When is ImmunityBio’s upcoming earnings report date?
ImmunityBio’s upcoming earnings report date is Aug 09, 2023 which is 260 days ago.
How were ImmunityBio’s earnings last quarter?
ImmunityBio released its earnings results on May 11, 2023. The company reported -€0.253 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.253.
Is ImmunityBio overvalued?
According to Wall Street analysts ImmunityBio’s price is currently Undervalued.
Does ImmunityBio pay dividends?
ImmunityBio does not currently pay dividends.
What is ImmunityBio’s EPS estimate?
ImmunityBio’s EPS estimate is -€0.22.
How many shares outstanding does ImmunityBio have?
Currently, no data Available
What happened to ImmunityBio’s price movement after its last earnings report?
ImmunityBio reported an EPS of -€0.253 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -10.18%.
Which hedge fund is a major shareholder of ImmunityBio?
Among the largest hedge funds holding ImmunityBio’s share is Harbourvest Partners Llc. It holds ImmunityBio’s shares valued at 2M.
---
ImmunityBio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€4.67 (4.21% Upside)
€4.67 (4.21% Upside)
Blogger Sentiment
Bullish
DE:26CA Sentiment 81%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
97.54%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
39.21%
Trailing 12-Months
Company Description
ImmunityBio
NantKwest, Inc. engages in the development of immunotherapies with a focus on harnessing the power of the innate immune system. It uses natural killer cells to treat cancer, infectious diseases, and inflammatory diseases. The firm operates through the following geographical segments: United States; Europe; and Other Non-U.S. The company was founded by Gary N. Keller and Hans Georg Klingemannon October 7, 2002 and is headquartered in San Diego, CA.
---
26CA Stock 12 Months Forecast
Average Price Target
€4.67
▲(4.21% Upside)
Technical Analysis
Best Analysts Covering 26CA
1 Year
1 Year Success Rate
1/3 ratings generated profit
1 Year Average Return
+23.13%
reiterated a buy rating 12 months ago
Copying Kelly Shi's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of +23.13% per trade.
---